Cytomegalovirus Prophylaxis with Letermovir in Heart Transplant Recipients: A Non-randomized Cohort Pilot Study

Phase 2

Not yet recruiting

• Conditions: CMV infection in heart transplant recipients

• Registration Number: 2024-517354-98-00
• Lead Sponsor: University Medical Center Ljubljana

Brief Summary

The primary objective of the study is to investigate the efficacy of letermovir-based CMV prophylaxis in patients after heart transplantation.

Detailed Description

Not available

Study Timeline

• Study First Posted: 2024-09-17
• Last Update Posted: 2024-09-17

Recruitment & Eligibility

• Status: Authorised, recruitment pending
• Sex: Not specified
• Target Recruitment: 90

Inclusion Criteria

•heart transplant recipient (new)

•moderate (D+/R+ and D-/R+) or high (D+/R-) risk CMV serostatus

•signed informed consent for participation in the study

• age ≥ 18 years

•not enrolled in competing clinical trials

Exclusion Criteria

•short-term mechanical circulatory support prior HTX

•known hypersensitivity to letermovir

•known hypersensitivity to valgancyclovir

•known hematological disorders (apart from anemia)

•history of malignancy (< 5 years; except adequately treated basal or squamous cell skin cancer or in situ cervical cancer) or under evaluation for active or suspected malignancy

•advanced kindey disease (CrCL < 10 ml/min) at enrollment

•advanced liver disease (Child Pugh Class C)

•combined moderate kidney (CrCL < 50 ml/min) and liver (Child Pugh Class B) insufficiency at screening

•concomitant administration with pimozide

•concomitant administration with ergot alkaloids

•concomitant administration with St. John’s wort (Hypericum perforatum)

•multi-organ transplantation

•concomitant administration of cyclosporine

•concomitant use of dabigatran, atorvastatin, simvastatin, rosuvastatin or pitavastatin is contraindicated

•known hereditary problems of galactose intolerance, total lactase deficiency or glucose-galactose malabsorption

•combined hepatic and renal impairment

•HIV infection

•Has a history or current evidence of any condition, therapy, lab abnormality, or other circumstance that might confound the results of the study, interfere with the participant's participation for the full duration of the study, or put the participant at undue risk, as judged by the investigator, such that it is not in the best interest of the participant to participate in this study

•Has previously participated in this study or any other study involving letermovir.

•Has previously participated or is currently participating in any study involving administration of a CMV vaccine or another CMV investigational agent, or is planning to participate in a study of a CMV vaccine or another CMV investigational agent during the course of this study.

•ongoing CMV infection/disease

•D-/R- CMV serostatus

•heart re-transplantation

•need for intensified immunosuppression protocol (>20% cytolytic alloantibodies prior transplant or perioperative (within 7 days after HTX) allograft rejection > 1R)

•immunoinduction with ATG

•pregnancy

•active participation in another interventional clinical trial

Study & Design

• Study Type: Not specified
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
The rate of early CMV infections/disease during virostatic prophylaxis.		The rate of early CMV infections/disease during virostatic prophylaxis.

Secondary Outcome Measures

Name	Time	Method
•The rate of late CMV infections/disease between virostatic discontinuation and 6 months thereafter.		•The rate of late CMV infections/disease between virostatic discontinuation and 6 months thereafter.
•The time-course of the restitution of cell-mediated immunity during virostatic prophylaxis		•The time-course of the restitution of cell-mediated immunity during virostatic prophylaxis
•The rate of leukopenia during virostatic prophylaxis		•The rate of leukopenia during virostatic prophylaxis
•The rate of neutropenia during virostatic prophylaxis		•The rate of neutropenia during virostatic prophylaxis
•The rate of CMV resistance to virostatic therapy.		•The rate of CMV resistance to virostatic therapy.

Trial Locations

Locations (1)

University Medical Center Ljubljana; 🇸🇮 Ljubljana, Slovenia

University Medical Center Ljubljana

🇸🇮Ljubljana, Slovenia

Bojan Vrtovec

Site contact

+38615222844

bojan.vrtovec@kclj.si